LNC
OCUL icon

Lincoln National Corp’s Ocular Therapeutix OCUL Stock Holding History

Lincoln National Corp’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,226
Closed -$521K – 787
2024
Q1 		$521K Hold
57,226
– – 0.01% 735
2023
Q4 		$255K Hold
57,226
– – ﹤0.01% 943
2023
Q3 		$180K Hold
57,226
– – ﹤0.01% 979
2023
Q2 		$295K Buy
+57,226
New +$340K 0.01% 798

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lincoln National Corp's OCUL Position: Q2 2024 in Review

Lincoln National Corp sold out of Ocular Therapeutix (OCUL) in Q2 2024, closing a stake of 57,226 shares — an estimated $521K sold.

Lincoln National Corp first reported a position in OCUL in Q2 2023 and held it in 4 quarters. The position peaked at $521K in Q1 2024. 150 funds tracked by Wall St. Rank hold OCUL as of Q2 2024.

  • Lincoln National Corp reported no remaining Ocular Therapeutix position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 57,226 Ocular Therapeutix shares in Q2 2024, an estimated $521K.
  • Lincoln National Corp first reported a position in Ocular Therapeutix in Q2 2023 and held it in 4 quarters.
  • Lincoln National Corp's Ocular Therapeutix position peaked at $521K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.